A Trial to Compare Pharmacokinetic Properties of Semaglutide Following Subcutaneous Administration of Semaglutide 1 mg by the DV3372 Device and by the PDS290 Semaglutide Pen-injector
Phase of Trial: Phase I
Latest Information Update: 21 Jan 2019
At a glance
- Drugs Semaglutide (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 11 Jan 2019 Status changed from active, no longer recruiting to completed.
- 29 Nov 2018 Planned End Date changed from 9 Jan 2019 to 2 Jan 2019.
- 29 Nov 2018 Planned primary completion date changed from 9 Jan 2019 to 2 Jan 2019.